Company news

Vyome Holdings, Inc. news in 2026

Vyome Holdings, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School

October 26, 2026

Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market

October 5, 2026

Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer

September 14, 2026

Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet

August 25, 2026

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

July 1, 2026

Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

May 27, 2026

Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

May 12, 2026

Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

April 22, 2026

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

April 6, 2026

Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

March 25, 2026

Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company

February 24, 2026

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

February 18, 2026

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

February 10, 2026

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

February 1, 2026

Decks in 2026